Physician profile
Robert C Allen
NPI 1639195977
$3,819.10
in general payments reported to CMS, 2019-2025
27 companies · $789 in 2025
The $789 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $255 · 2021: $562 · 2022: $708 · 2023: $567 · 2024: $685 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,041.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $752.37 | 2020-2025 | Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $416.20 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $414.34 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $300.03 | 2019-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $192.10 | 2019-2025 | |
| Lilly USA, LLC | $190.15 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $181.37 | 2023-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.03 | 2020-2025 | Jardiance |
| Baxter Healthcare | $174.24 | 2022 | |
| Astellas Pharma US INC | $133.48 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $120.76 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $113.80 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $96.80 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $82.23 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $67.06 | 2020-2024 | Capvaxive, Gardasil, Gardasil 9 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $54.15 | 2019-2021 | |
| Viatris Specialty LLC | $53.64 | 2025 | Yupelri |
| Sumitomo Pharma America, INC. | $52.95 | 2023-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $46.78 | 2023-2024 | Glassia, Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.94 | 2019-2024 | Xifaxan |
| Amneal Pharmaceuticals LLC | $33.20 | 2024 | Unithroid |
| Ultragenyx Pharmaceutical INC. | $23.91 | 2023 | |
| Phathom Pharmaceuticals, INC. | $21.97 | 2025 | Voquezna |
| Boston Scientific Corporation | $21.74 | 2020 | |
| Mylan Specialty L.P. | $16.70 | 2024 | Yupelri |
| Eisai INC. | $16.63 | 2021 | |
| Allergan, INC. | $16.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.